• Cessatech posted no revenue in Q2 2026; operating loss widened to DKK 3.47 million.
• Net loss totaled DKK 2.77 million; earnings per share came in at DKK -0.15.
• Cash at bank was DKK 2.35 million at period-end; solidity stood at 77%.
• Management flagged release of the first commercial CT001 batch in the U.S., enabling launch activities with selected hospitals.
• In Europe, the company is pursuing a re-examination process with Proveca following a negative CHMP opinion on KemSu/CT001.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cessatech A/S published the original content used to generate this news brief via Cision (Ref. ID: 20260828:BIT:3298:0) on August 28, 2026, and is solely responsible for the information contained therein.